Renovacare Inc (RCAR) 1.6200 $RCAR CORRECTING a
Post# of 273315
Posted On: 08/16/2016 9:01:38 PM
Renovacare Inc (RCAR) 1.6200 $RCAR
CORRECTING and REPLACING VIDEO Latest Test Results Bolster RenovaCare Strategy to Spray Stem Cells on Wounds and Burns for Rapid Healing
BusinessWire - Tue May 31, 10:29AM CDT
Please replace the video with the accompanying corrected video.
Latest Test Results Bolster RenovaCare Strategy to Spray Stem Cells on Wounds and Burns for Rapid Healing
BusinessWire - Tue May 31, 8:57AM CDT
RenovaCare, Inc., (OTCQB:RCAR) today announced positive spray test results demonstrating that its novel SkinGun(TM) technology achieves exceptionally-uniform distribution of fluids with 200 times greater coverage than conventional methods. These outcomes are especially promising to scientists developing patented RenovaCare CellMist(TM) and SkinGun(TM) technologies* for spraying fluids containing a patient's own stem cells onto burns and wounds for rapid scar-free healing.
New Study: RenovaCare SkinGun(TM) Ultra-Gently Sprays Human Stem Cells to Achieve 'Gold-Standard' Viability for Skin Regeneration
BusinessWire - Tue May 03, 8:15AM CDT
RenovaCare, Inc., (OTCQB:RCAR), a developer of novel medical grade liquid spray devices and patented CellMist(TM) and SkinGun(TM) technologies*, today announced favorable outcomes from laboratory studies conducted by Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charite - Universitatsmedizin Berlin, one of the world's largest university hospitals.
RenovaCare, Inc. Completes Engineering, Research, and Studies Required to File 510(k) Submission to the FDA for its Novel Medical-Grade Liquid Spray Device
BusinessWire - Tue Apr 12, 8:15AM CDT
RenovaCare, Inc., a developer of novel medical grade liquid spray devices and patented CellMist(TM) and SkinGun(TM) technologies* for isolating and spraying a patient's own stem cells onto burns and wounds for rapid self-healing, today announced that the company has successfully completed the engineering, studies, and associated efforts required for submission of its foundational 510(k) filing to the U.S. Food and Drug Administration (FDA). The company's planned submission will focus on its liquid sprayer technology. The FDA's clearance of a 510(k) submission allows for the marketing of a medical device in the United States.
RenovaCare, Inc. Names Renowned Skin Surgeon Steven Q. Wang, MD to Board of Advisors
BusinessWire - Tue Feb 09, 8:15AM CST
RenovaCare, Inc., developer of patented CellMist(TM) and SkinGun(TM) technologies* for isolating and spraying a patient's own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of Steven Q. Wang to its Board of Advisors. Dr. Wang is Head of Dermatology Section and Director of Dermatologic Surgery and Dermatology at Memorial Sloan-Kettering Cancer Center in Basking Ridge, New Jersey.
Respected Plastic and Reconstructive Surgeon, Richard Simman, MD, Joins RenovaCare, Inc.
BusinessWire - Tue Jan 12, 8:15AM CST
RenovaCare, Inc., developer of the patented CellMist(TM) and SkinGun(TM) technologies* for isolating and spraying a patient's own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of board certified plastic and reconstructive surgeon, Richard Simman, MD, FACS, and FACCWS, to its Board of Advisors.
RenovaCare, Inc. Enters R&D Partnership with World Leading Charite
BusinessWire - Tue Nov 17, 8:15AM CST
RenovaCare, Inc. (OTCQB:RCAR), today announced a partnership to validate the science behind its groundbreaking technology for treatments of wounds, burns and other skin defects. The company's research partner is Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charite - Universitatsmedizin Berlin, one of the world's largest university hospitals.
RenovaCare elects Michael M. Barch to board of advisors
M2 - Fri Oct 16, 3:06AM CDT
Stem cell therapies company RenovaCare (OTC BB:RCAR) reported on Thursday the addition of Michael M. Barch to its board of advisors.
Accomplished Healthcare Executive, Michael M. Barch, Joins RenovaCare, Inc.
BusinessWire - Thu Oct 15, 8:15AM CDT
RenovaCare, Inc., (OTCQB:RCAR), developer of the patented CellMist(TM) and SkinGun(TM) technologies for isolating and spraying a patient's own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of healthcare executive and industry thought-leader, Michael M. Barch, to its Board of Advisors.
CORRECTING and REPLACING VIDEO Latest Test Results Bolster RenovaCare Strategy to Spray Stem Cells on Wounds and Burns for Rapid Healing
BusinessWire - Tue May 31, 10:29AM CDT
Please replace the video with the accompanying corrected video.
Latest Test Results Bolster RenovaCare Strategy to Spray Stem Cells on Wounds and Burns for Rapid Healing
BusinessWire - Tue May 31, 8:57AM CDT
RenovaCare, Inc., (OTCQB:RCAR) today announced positive spray test results demonstrating that its novel SkinGun(TM) technology achieves exceptionally-uniform distribution of fluids with 200 times greater coverage than conventional methods. These outcomes are especially promising to scientists developing patented RenovaCare CellMist(TM) and SkinGun(TM) technologies* for spraying fluids containing a patient's own stem cells onto burns and wounds for rapid scar-free healing.
New Study: RenovaCare SkinGun(TM) Ultra-Gently Sprays Human Stem Cells to Achieve 'Gold-Standard' Viability for Skin Regeneration
BusinessWire - Tue May 03, 8:15AM CDT
RenovaCare, Inc., (OTCQB:RCAR), a developer of novel medical grade liquid spray devices and patented CellMist(TM) and SkinGun(TM) technologies*, today announced favorable outcomes from laboratory studies conducted by Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charite - Universitatsmedizin Berlin, one of the world's largest university hospitals.
RenovaCare, Inc. Completes Engineering, Research, and Studies Required to File 510(k) Submission to the FDA for its Novel Medical-Grade Liquid Spray Device
BusinessWire - Tue Apr 12, 8:15AM CDT
RenovaCare, Inc., a developer of novel medical grade liquid spray devices and patented CellMist(TM) and SkinGun(TM) technologies* for isolating and spraying a patient's own stem cells onto burns and wounds for rapid self-healing, today announced that the company has successfully completed the engineering, studies, and associated efforts required for submission of its foundational 510(k) filing to the U.S. Food and Drug Administration (FDA). The company's planned submission will focus on its liquid sprayer technology. The FDA's clearance of a 510(k) submission allows for the marketing of a medical device in the United States.
RenovaCare, Inc. Names Renowned Skin Surgeon Steven Q. Wang, MD to Board of Advisors
BusinessWire - Tue Feb 09, 8:15AM CST
RenovaCare, Inc., developer of patented CellMist(TM) and SkinGun(TM) technologies* for isolating and spraying a patient's own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of Steven Q. Wang to its Board of Advisors. Dr. Wang is Head of Dermatology Section and Director of Dermatologic Surgery and Dermatology at Memorial Sloan-Kettering Cancer Center in Basking Ridge, New Jersey.
Respected Plastic and Reconstructive Surgeon, Richard Simman, MD, Joins RenovaCare, Inc.
BusinessWire - Tue Jan 12, 8:15AM CST
RenovaCare, Inc., developer of the patented CellMist(TM) and SkinGun(TM) technologies* for isolating and spraying a patient's own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of board certified plastic and reconstructive surgeon, Richard Simman, MD, FACS, and FACCWS, to its Board of Advisors.
RenovaCare, Inc. Enters R&D Partnership with World Leading Charite
BusinessWire - Tue Nov 17, 8:15AM CST
RenovaCare, Inc. (OTCQB:RCAR), today announced a partnership to validate the science behind its groundbreaking technology for treatments of wounds, burns and other skin defects. The company's research partner is Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charite - Universitatsmedizin Berlin, one of the world's largest university hospitals.
RenovaCare elects Michael M. Barch to board of advisors
M2 - Fri Oct 16, 3:06AM CDT
Stem cell therapies company RenovaCare (OTC BB:RCAR) reported on Thursday the addition of Michael M. Barch to its board of advisors.
Accomplished Healthcare Executive, Michael M. Barch, Joins RenovaCare, Inc.
BusinessWire - Thu Oct 15, 8:15AM CDT
RenovaCare, Inc., (OTCQB:RCAR), developer of the patented CellMist(TM) and SkinGun(TM) technologies for isolating and spraying a patient's own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of healthcare executive and industry thought-leader, Michael M. Barch, to its Board of Advisors.
(0)
(0)